NasdaqGS:SRPTBiotechs
Sarepta Therapeutics (NasdaqGS:SRPT) Faces Shipment Suspension Amid Safety Update
Sarepta Therapeutics (NasdaqGS:SRPT) recently provided updates that may have influenced its stock performance. The announcement of a safety update for ELEVIDYS, concerning severe side effects and a temporary shipment suspension for non-ambulatory patients with Duchenne muscular dystrophy, likely exerted significant pressure on the stock, resulting in a 16% decline last week. Additionally, the market's positive momentum, with a 1.7% increase, contrasts sharply with Sarepta’s downturn,...